{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV+Specific+T-Lymphocytes&page=2",
    "query": {
      "intervention": "EBV Specific T-Lymphocytes",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV+Specific+T-Lymphocytes&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T11:18:50.952Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02048332",
      "title": "Donor-Derived Viral Specific T-cells (VSTs)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Stem Cell Transplant",
        "Viral Infection",
        "Viral Reactivation"
      ],
      "interventions": [
        {
          "name": "Viral specific VST Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Weeks and older"
      },
      "enrollment_count": 1000,
      "start_date": "2014-02-05",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 3,
      "location_summary": "Akron, Ohio • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02048332"
    },
    {
      "nct_id": "NCT02231853",
      "title": "Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "CML (Chronic Myelogenous Leukemia)",
        "MDS (Myelodysplastic Syndrome)",
        "Acute Lymphoblastic Leukemia",
        "AML (Acute Myelogenous Leukemia)"
      ],
      "interventions": [
        {
          "name": "MVST",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVSTr",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-09-03",
      "completion_date": "2017-12-29",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02231853"
    },
    {
      "nct_id": "NCT02510404",
      "title": "Multivirus-specific Cytotoxic T Lymphocytes (mCTL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Viral Infections"
      ],
      "interventions": [
        {
          "name": "mCTLs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catherine Bollard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 45 Years"
      },
      "enrollment_count": 1,
      "start_date": "2014-04",
      "completion_date": "2019-06-08",
      "has_results": false,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510404"
    },
    {
      "nct_id": "NCT07729397",
      "title": "Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B-Cell Lymphoma (DLBCL)",
        "Hodgkin Lymphoma",
        "Peripheral T-cell Lymphoma (PTCL)",
        "Anaplastic Large Cell Lymphoma, ALK-Positive",
        "Anaplastic Large Cell Lymphoma, ALK-Negative"
      ],
      "interventions": [
        {
          "name": "Autologous C7R.CD30-CAR-EBVSTs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "16 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2027-01-15",
      "completion_date": "2044-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07729397"
    },
    {
      "nct_id": "NCT02900976",
      "title": "Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EBV-Related Post-Transplant Lymphoproliferative Disorder",
        "Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder",
        "Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "ALL",
        "summary": "Up to 29 Years"
      },
      "enrollment_count": 18,
      "start_date": "2017-03-22",
      "completion_date": "2025-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900976"
    },
    {
      "nct_id": "NCT02532452",
      "title": "Third Party Viral Specific T-cells (VSTs)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Viral Infection",
        "Viral Reactivation",
        "Infection in an Immunocompromised Host"
      ],
      "interventions": [
        {
          "name": "Viral Specific VST Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Days",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Days and older"
      },
      "enrollment_count": 1000,
      "start_date": "2015-09-02",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 4,
      "location_summary": "Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio",
      "locations": [
        {
          "city": "Akron",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02532452"
    },
    {
      "nct_id": "NCT00002956",
      "title": "Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 0,
      "start_date": "1996-11",
      "completion_date": "2002-02",
      "has_results": false,
      "last_update_posted_date": "2016-03-21",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002956"
    },
    {
      "nct_id": "NCT00058812",
      "title": "Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epstein-Barr Virus Infections"
      ],
      "interventions": [
        {
          "name": "EBV specific T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 69,
      "start_date": "1993-05",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2015-01-29",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00058812"
    },
    {
      "nct_id": "NCT02287311",
      "title": "Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hodgkin Disease",
        "Non-Hodgkin Lymphoma",
        "Severe Chronic Active Epstein Barr Virus",
        "T/NK-lymphoproliferative Disease",
        "Nasopharyngeal Carcinoma",
        "Smooth Muscle Tumor"
      ],
      "interventions": [
        {
          "name": "MABEL CTLs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 38,
      "start_date": "2015-02",
      "completion_date": "2029-03",
      "has_results": true,
      "last_update_posted_date": "2026-03-23",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287311"
    },
    {
      "nct_id": "NCT02973113",
      "title": "Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NonHodgkin Lymphoma",
        "Lymphoproliferative Disorders",
        "EBV Related Lymphoma",
        "EBV-Related PTLD",
        "Hodgkin Lymphoma",
        "EBV Related Non-Hodgkin's Lymphoma",
        "EBV Related Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "EBVST Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 8,
      "start_date": "2016-02-16",
      "completion_date": "2020-07-11",
      "has_results": false,
      "last_update_posted_date": "2021-07-21",
      "last_synced_at": "2026-09-29T11:18:50.952Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02973113"
    }
  ]
}